Company Profile
Exelixis Stock Price, News & Analysis
- Ticker:
- EXEL
- Exchange:
- NASDAQ
- Sector:
- Small Molecule Drugs
- Location:
- United States
Stock performance
52.20 USD (-7.94%)
Close
Last updated: August 6, 2026
12.2B USD
Market cap
Why the stock is moving
Following the latest company update, “Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update”, EXEL closed down 7.94% at $52.20 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Commercial Oncology Company
Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations.
Cabozantinib Franchise
Cabozantinib is the company’s principal commercial asset and is marketed in the United States under the CABOMETYX brand across multiple tumor types. The franchise gives Exelixis an established commercial and clinical-development infrastructure in renal, liver and thyroid cancers.
Zanzalintinib Franchise
Zanzalintinib is a next-generation tyrosine kinase inhibitor being studied in numerous pivotal and signal-seeking trials. The program includes combinations with atezolizumab, WELIREG and chemotherapy across colorectal, renal, lung, prostate and other cancers.
Colorectal Cancer Registration
An NDA is under FDA review for zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer. The filing is supported by the Phase 3 STELLAR-303 trial, which demonstrated an overall-survival benefit versus regorafenib in the intent-to-treat population.
Broad Clinical Expansion
The portfolio includes the Phase 3 STELLAR-304, STELLAR-311, STELLAR-316 and LITESPARK-034 studies, as well as Phase 2 programs in recurrent meningioma and planned work in lung cancer. This breadth is intended to establish zanzalintinib as a second major Exelixis franchise.
Future catalysts
Final STELLAR-303 overall-survival analysis in patients without liver metastases expected in mid-2026, subject to event timing.
Initiation of the Phase 3 STELLAR-316 trial expected in mid-2026.
Topline results from the Phase 3 STELLAR-304 trial expected in the second half of 2026.
FDA action on the zanzalintinib-plus-atezolizumab NDA expected by December 3, 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Exelixis (EXEL)?
Exelixis (EXEL) most recently closed at 52.20 USD, a -7.94% move versus the previous session.
What is the market cap of Exelixis (EXEL)?
Exelixis currently has a market capitalization of 12.2B USD on BioPharmSignal.
What does Exelixis do?
Commercial Oncology Company Exelixis develops and commercializes therapies for genitourinary and gastrointestinal cancers. Revenue from its established cabozantinib franchise funds a broad effort to create additional oncology products and combinations. Cabozantinib Franchise Cabozantinib is the company’s principal commercial asset and is marketed in the...
On which exchange is EXEL stock listed?
Exelixis (EXEL) is associated with NASDAQ, United States, Small Molecule Drugs.
What is STELLAR-303?
Final STELLAR-303 overall-survival analysis in patients without liver metastases expected in mid-2026, subject to event timing.
Which conditions is Exelixis targeting with STELLAR-303?
Exelixis is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Exelixis describe recent progress with STELLAR-303?
Final STELLAR-303 overall-survival analysis in patients without liver metastases expected in mid-2026, subject to event timing.
What is STELLAR-304?
Broad Clinical Expansion The portfolio includes the Phase 3 STELLAR-304, STELLAR-311, STELLAR-316 and LITESPARK-034 studies, as well as Phase 2 programs in recurrent meningioma and planned work in lung cancer.